



ALMEDA VENTURES

ACHIEVING IN HEALTHCARE



The information included in this presentation is a summary only and does not exhaust all of the information on the Partnership and its business, nor is it a substitute for inspection of the Partnership's current reports and the presentations released thereby, as reported to the ISA via the Magna distribution site. The presentation does not constitute an offering or an invitation to purchase securities of the Partnership, and the provisions thereof do not constitute a recommendation or opinion or substitute for the discretion of the investor. The Partnership is not responsible for the integrity or accuracy of the information.

This presentation includes forecasts, estimates, assessments and other information pertaining to future events and/or matters, whose materialization is uncertain and is beyond the Partnership's control, and which constitute forward-looking information, as defined in the Securities Law, 5728-1968. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different to that forecast. Forward-looking information is based solely on the Partnership's subjective assessment, based on facts and data regarding the current condition of the Partnership's business and macroeconomic facts and figures, all as known to the Partnership at the time of preparation of this presentation. The materialization or non-materialization of the forward-looking information will be affected, inter alia, by risk factors characteristic of the Partnership's activity, as well as by developments in the general environment, in market conditions and in external factors affecting the Partnership's activity, and other such events which cannot be estimated in advance and which are beyond the Partnership's control. The Partnership does not undertake to update and/or change any such forecast and/or assessment to reflect events and/or circumstances postdating this presentation.

This presentation includes publications and other figures and statistics that are based on external sources and various surveys and studies. The Company is not responsible for the veracity or content thereof, nor for forecasts in respect thereof.

The information included in this presentation is similar to the information included in the reports and/or immediate reports of the Partnership and does not include new material information. However, some of the data included in the presentation are presented in a different manner and/or breakdown and/or are differently edited. In any event of inconsistency between the reports and/or immediate reports of the Partnership released to the public and the information contained in this presentation, the information released to the public as aforesaid shall prevail.

All numbers and figures are approximate.

Until now,
HealthTech Investments were
predominantly available
through private funds;

Almeda Ventures is making
HealthTech Investments
Accessible to the Public



Almeda Ventures – Lead Team

- Extensive experience in HealthTech Investments and capital markets
- Over a decade of collaborative team experience as part of Accelmed Fund



Dr. Irit Yaniv
Co-Founder, CEO

Dr. Yaniv (MD, MBA) has more than 25 years of experience in the venture capital, pharmaceutical and biotech industries.



Served as partner at Accelmed since 2001. As an Executive Director and Chairperson of Accelmed's Innovation Hub portfolio companies. Led Eximo from pre-clinical development through acquisition.



Amir Blatt
Co-Founder, CIO

Previously, as a partner at Accelmed Fund, Amir was a leader in the Digital Health field.

During his tenure at Accelmed, Amir was responsible for investments totaling more than \$200M.

Amir is a Biotechnology engineer from the Technion-Israel Institute of Technology and holds an MBA from Tel Aviv University



Tzahi Sultan
Co-Founder

One of the most prominent figures in the Israeli financial market


Serves as Chairman of Discount Capital Underwriting

Joined Discount Capital after it merged with Clal Finance Underwriting, the leading underwriting firm in Israel which he founded more than 20 years ago

Almeda Ventures – Managed by an Accomplished Team

The first public R&D Life Science partnership






**Almeda
Ventures**
The Next Generation of
HealthTech Investments

Almeda Ventures – A Strong and Solid EcoSystem

Established Collaborations & Partnerships



Almeda Ventures

Investment Strategy



Investment in HealthTech Technologies focusing on better efficiency of medical processes and outcomes

- Investment in Digital health technologies
- Investment in Medical Device companies developing unique offerings
- Investment in Bio-Convergence solutions

- The partnership may invest in companies at various stages; and will aim for a board position

- Initial investment will not be higher than 40% of the partnership capital

- The partnership may set syndication for particular investment opportunities



Digital Health is Transforming Medicine

Capabilities like data collection, data recording, data analysis are changing the way we approach medicine today



Patient
Centered



Monitoring/
Diagnostic



Predicting &
Preventing
Diseases



Remote
Patient Care



Personalized
Medicine



Digital Health

Promising Investment with a Rapid Growth Curve

24% Growth in
Q2/20
Compared to
Q2 2019

\$1 out
of \$10
Venture money goes
to digital health

\$13B
Market Cap
IPOs in 2019

112 M&A
deals
In 2019

Estimated Digital Health market could
grow ~\$500B over the next 5-6 years




*Estimate
Note: CAGR = Compounded Annual Growth Rate
Source: Roland Berger, Global X ETFs, 2020.

Medical Devices

A solid area for Investment

Today as well as in the past, Israeli medical device companies present attractive acquisition opportunities for MNCs



An aging population and prevalence of chronic diseases create high demand for innovative products / services that improve medical care

Multi-national companies seek external innovation following mega-mergers integration

Knowledge and experience on development processes, accelerate potential growth and allows for better return on investment

Due to limited funding over the last decade, there are multiple investment opportunities with reasonable valuations

Bio-Convergence

The Future of Medicine




Background


- The global health systems and bio-pharm industry are in crisis. This has been caused by a sharp increase in health expenditures and in the development costs of new medicines
- Technological breakthroughs achieved in recent years enable us to connect and combine fields in ways that were previously impossible



Examples

- Nanorobotics for drug delivery
- Biological Sensors and Diagnostics
- Optogenetics
- 3D Tissue Bio-Printing





Almeda Ventures

A Portfolio Company

Bio Protect

Oncology Field

- An Israeli company, producing a biodegradable balloon spacer for prostate cancer radiotherapy
- Augmenix, has paved the way, by establishing the clinical utility, coding, coverage and commercial potential of the US Spacer Market, leading to Augmenix's acquisition by Boston Scientific, ~\$600m (Oct 2018)
- Reimbursement is in place
- Round D financing aims to complete IDE study and obtain FDA approval,
- To date, \$25M invested
- Dr. Irit Yaniv, serves as chairperson
- Partnership holds 7%
- Additional Investors: CBG, KBI and Triventures , Peregrine and the largest medical device multinational company

Almeda Ventures

A Portfolio Company

TAILORMED



Tailormed

Comprehensive financial navigation platform

- An Israeli company, developing and selling a comprehensive solution for reducing the financial burden on US patients
- Using data and advanced analytics, the platform's products streamline all steps of the process, from benefit investigation and out of pocket estimation to enrollment and management of approved programs.
- Investment rational
 - US sales growth
 - Huge market potential more than 6,000 relevant US health centers
 - Use of proceeds for sales growth and extension for more clinical segments
- Almeda invested \$1M in SAFE, ahead of the expected B round
- Amir Blatt represents Accelmed on the Board
- Additional investors: Sanara, Philips, Triventures and Accelmed

Almeda Ventures

Partnership Terms



Capital Raise

At IPO, we have raised ~\$20M



Investment Structure

Publicly traded – AMDA.L



Success Fee

Exit Event: 20% carry out of the returns in cash, pending that NAV is higher than the capital raised (with deduction of the return)



Management Fee

- 0.8% (up to \$120M)
- 0.6% (between \$120M-\$240M)
- 0.5% (\$240M and above)

Almeda Ventures

Summation



**Evergreen fund
Co-investment opportunities**

**Investing in promising medical
devices, digital health and bio-
convergence technologies in
Israel and globally**

**Public R&D Partnership
With high potential and unique structure**

**An experienced team with a
proven track record**

**Seeking strong management
teams, to introduce to a broad
eco-system**



ACHIEVING IN HEALTHCARE

Thank You